Noga Kozer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Noga Kozer has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
- Inna Goliand
Life Sciences Core Facilities Weizmann Institute of Science Rehovot Israel
22 shared publications - Alexander Brandis
Weizmann Institute of Science 5 Department of Life Sciences Core Facilities Rehovot, Israel
20 shared publications - Amir Shlomai
Department of Medicine D, Rabin Medical Center, Beilinson Campus, Petah-Tikva, Israel; Laboratory of Liver Research, The Felsenstein Medical Research Center, Beilinson Campus, Petah Tikva, Israel; Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel
20 shared publications - Ayelet Erez
Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot 7610001, Israel
20 shared publications - David Robert Crawford
National Cancer Institute 4 Cancer Data Science Lab, Center for Cancer Research National Institutes of Health, Bethesda, Maryland
20 shared publications - Dean Ranmar
Weizmann Institute of Science 5 Department of Life Sciences Core Facilities Rehovot, Israel
20 shared publications
Latest Publications
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from PDE5A Inhibition Restricts Cancer Metastasis by Disrupting NPC1-Mediated Cholesterol Trafficking through a Noncanonical cGMP-Dependent Pathway
Features of chosen cell lines for DepMap analysis
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from PDE5A Inhibition Restricts Cancer Metastasis by Disrupting NPC1-Mediated Cholesterol Trafficking through a Noncanonical cGMP-Dependent Pathway
Features of chosen cell lines for DepMap analysis
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 10 from PDE5A Inhibition Restricts Cancer Metastasis by Disrupting NPC1-Mediated Cholesterol Trafficking through a Noncanonical cGMP-Dependent Pathway
Characteristics of patients’ dispensing history of papaverin and statins up to 6 months prior to cancer diagnosis
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 10 from PDE5A Inhibition Restricts Cancer Metastasis by Disrupting NPC1-Mediated Cholesterol Trafficking through a Noncanonical cGMP-Dependent Pathway
Characteristics of patients’ dispensing history of papaverin and statins up to 6 months prior to cancer diagnosis
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 11 from PDE5A Inhibition Restricts Cancer Metastasis by Disrupting NPC1-Mediated Cholesterol Trafficking through a Noncanonical cGMP-Dependent Pathway
HR status of cancer patients used in papaverine cohort
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 11 from PDE5A Inhibition Restricts Cancer Metastasis by Disrupting NPC1-Mediated Cholesterol Trafficking through a Noncanonical cGMP-Dependent Pathway
HR status of cancer patients used in papaverine cohort
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 5 from PDE5A Inhibition Restricts Cancer Metastasis by Disrupting NPC1-Mediated Cholesterol Trafficking through a Noncanonical cGMP-Dependent Pathway
Hazard ratio (HR) status of cancer patients used in the cohort
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 5 from PDE5A Inhibition Restricts Cancer Metastasis by Disrupting NPC1-Mediated Cholesterol Trafficking through a Noncanonical cGMP-Dependent Pathway
Hazard ratio (HR) status of cancer patients used in the cohort
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 4 from PDE5A Inhibition Restricts Cancer Metastasis by Disrupting NPC1-Mediated Cholesterol Trafficking through a Noncanonical cGMP-Dependent Pathway
Characteristics of patients’ dispensing history of sildenafil and statins up to 6 months prior to cancer diagnosis
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 4 from PDE5A Inhibition Restricts Cancer Metastasis by Disrupting NPC1-Mediated Cholesterol Trafficking through a Noncanonical cGMP-Dependent Pathway
Characteristics of patients’ dispensing history of sildenafil and statins up to 6 months prior to cancer diagnosis
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 6 from PDE5A Inhibition Restricts Cancer Metastasis by Disrupting NPC1-Mediated Cholesterol Trafficking through a Noncanonical cGMP-Dependent Pathway
Characteristics of male patients’ dispensing history of sildenafil and statins up to 6 months prior to cancer diagnosis
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 6 from PDE5A Inhibition Restricts Cancer Metastasis by Disrupting NPC1-Mediated Cholesterol Trafficking through a Noncanonical cGMP-Dependent Pathway
Characteristics of male patients’ dispensing history of sildenafil and statins up to 6 months prior to cancer diagnosis
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 8 from PDE5A Inhibition Restricts Cancer Metastasis by Disrupting NPC1-Mediated Cholesterol Trafficking through a Noncanonical cGMP-Dependent Pathway
Characteristics of diabetic patients’ dispensing history of sildenafil and statins up to 6 months prior to cancer diagnosis
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 8 from PDE5A Inhibition Restricts Cancer Metastasis by Disrupting NPC1-Mediated Cholesterol Trafficking through a Noncanonical cGMP-Dependent Pathway
Characteristics of diabetic patients’ dispensing history of sildenafil and statins up to 6 months prior to cancer diagnosis